Insulin resistance, diabetes and cardiovascular risk: Approaches to treatment

Diabetes, Obesity and Metabolism

Volumn 7, Issue 6, 2005, Pages 642-653

  Rosenberg, Daniel E ^a   Jabbour, Serge A ^a   Goldstein, Barry J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Exercise; Impaired glucose tolerance; Insulin therapy; Lifestyle modification; Metabolic syndrome; Metformin; Obesity; Sulphonylureas; Thiazolidinediones; Type 2 diabetes; Weight loss

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ADENYLATE KINASE; ALPHA GLUCOSIDASE INHIBITOR; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; CATECHOLAMINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GELATINASE B; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; METFORMIN; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

BLEEDING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATECHOLAMINE RELEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC HYPERTENSION; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DISEASE CONTROL; DOSE RESPONSE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DYSLIPIDEMIA; FLATULENCE; FLUID RETENTION; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LACTIC ACIDOSIS; LIFESTYLE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PERIPHERAL EDEMA; PHYSICAL ACTIVITY; POPULATION RESEARCH; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TOBACCO; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 27744473601     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00446.x     Document Type: Review

References (89)

1. Stamler J, Vaccarro O, Neaton JD, Wentword D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial (MR FIT). Diabetes Care 1993; 16: 434-444.
2. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281: 1291-1297.
3. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985; 110: 1100-1107.
4. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
5. Lee CD, Folsom AR, Pankow JS et al. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004; 109: 855-860.
6. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-1146.
7. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease - An update. Hypertension 2001; 37: 1053-1059.
8. Bloomergarden Z. Obesity, Hypertenion, and Insulin Resistance. Diabetes Care 2002; 25: 2088-2097.
9. Bigazzi R, Bianchi S, Baldari G et al. Clustering of cardiovasulcar risk factors in salt-sensitive patients with essential hypertension: role of insulin. Am J Hypertens 1995; 9: 24-32.
10. Davidson MB. Clinical implications of insulin resistance syndrome. Am J Med 1995; 99: 420-426.
11. Stampfer MJ, Krauss RM, Ma J et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882-888.
12. Lamarche B, Tchernoff A, Mauriege P et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955-1961.
13. Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003; 92: 10J-17J.
14. Manson JE, Ajani UA, Liu S et al. A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians. Am J Med 2000; 109: 538-542.
15. Shimokata H, Muller DC, Andres R. Studies in the distribution of body fat. Effects of cigarette smoking. JAMA 1989; 261: 1169-1173.
16. Smith SR, Lovejoy JC, Greenway F et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism 2001; 50: 425-435.
17. Bays H, Mandarino L, DeFronzo RA. Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach. J Clin Endocrinol Metab 2004; 89: 463-478.
18. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004; 89: 447-452.
19. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res 2004; 59: 207-223.
20. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2003; 288: 2709-2716.
21. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris prospective study. Diabetes Care 1991; 14: 461-469.
22. Pyorala M, Miettinen H, Laakso M et al. Hyperinsulinemia predicts coronary heart disease risk in healthy middle aged men: the 22 year follow up results of the Helsinki Policemen Study. Circulation 1997; 95: 69-75.
23. Haffner SM. Obesity and the metabolic syndrome: the San Antonio Heart Study. Br J Nutr 2000; 83 (Suppl. 1): S67-S70.
24. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977.
25. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes. UK Prospective Diabetes Study 35. BMJ 2000; 321: 405-412.
26. Intensive Diabetes Therapy and Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus. (The DCCT/EDIC Research Group). N Engl J Med 2003; 348: 2294-2303.
27. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
28. Jialal I, Stein D, Balis D et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-1935.
29. Gray RP, Patterson DL, Yudkin JS. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infacrtion. Arterioscler Thromb 1993; 13: 415-420.
30. Kai H, Ikeda H, Yasukawa H et al. Peripheral blood levels of matrix metalloproteases-2 and - 9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-372.
31. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
32. Brand-Miller J, Hayne S, Petocz P et al. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2003; 26: 2261-2267.
33. Bell RA, Mayer-Davis EJ, Martin MA et al. Associations between alcohol consumption and insulin sensitivity and cardiovascular disease risk factors: the Insulin Resistance and Atherosclerosis Study. Diabetes Care 2000; 23: 1630-1636.
34. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003; 289: 2560-2572.
35. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes. UK Prospective Diabetes Study 36. BMJ 2000; 321: 412-419.
36. Curb ID, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA; 996: 1886-1892.
37. Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. Systolic hypertension Europe trial investigators. N Engl J Med 1999; 340: 677-684.
38. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.
39. Yusuf S, Phil D, Sleight P et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
40. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losdartan Intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
41. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-2997.
42. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383-1389.
43. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
44. Downs JR, Clearfield M, Weis S et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results AFCAPS/TexCAPS. JAMA 1998; 279: 1615-1622.
45. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vacular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360: 1623-1630.
46. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-239.
47. Cannon CP, Braunwald E, McCabe CH et al. Pravastatin or Atorvastatin Evaluation and Infection therapy-Thrombolysis in Myocardial Infarction. Intensive versus moderate lipid lowering with statins after acte coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
48. Nissen SE, Tuzcu EM, Schoenhagen P et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-1080.
49. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
50. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.
51. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990; 13: 153-169.
52. Elam MB, Hunninghake DB, Davis KB et al. for the Arterial Disease Multiple Intervention Trial. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA 2000; 284: 1263-1270.
53. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed) 1988; 296: 320-331.
54. Khaw KT, Wareham N, Luben R et al. Glycated hemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322: 15-18.
55. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
56. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
57. DeFronzo RA, Goodman AM, Abelove W et al. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541-549.
58. Wulffele MG, Kooy A, De Zeeuw D et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus; a systematic review. Br J Clin Pharmacol 2002; 53: 549P-550P.
59. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33.
60. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999; 22: 925-927.
61. Aguilar-Bryan L, Nichols CG, Wechsler SW et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regular of insulin secretion. Science 1995; 268: 423-426.
62. Riddle MC. Editorial: sulfonylureas differ in effects on ischemic preconditioning-is is time to retire glyburide? J Clin Endocrinol Metab 2003; 88: 528-530.
63. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003; 88: 531-537.
64. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycomic control over 3 years. Diabetes Care 1999; 22: 960-964.
65. Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494.
66. Goke B, Herrmann C, Goke R et al. Intestinal effects of [alpha]-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur J Clin Invest 1994; 24 (Suppl. 3): 25-30.
67. Seifarth C, Begmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to [alpha]-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabet Med; 15: 485-491.
68. Vidal-Puig AJ, Considine RV, Jimenez-Linan M et al. Peroxisome proliferators-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99: 2416-2422.
69. Peterson KF, Krssak M, Inzucchi S et al. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000; 49: 827-831.
70. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferators-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1757-1763.
71. Phillips SA, Ciaraldi TP, Kong AP et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003; 52: 667-674.
72. Freed MI, Ratner R, Marcovina SM et al. Effects of rosiglitazone alone and in combination with atorvastain on the etabolic abnormalities of type 2 diabetes. Am J Cardiol 2002; 90: 947-952.
73. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000; 106: 467-472.
74. Ovalle F, Bell DS. Lipoprotein effects of different thiazolidinediones in clinical practice. Endocr Pract 2002; 8: 406-410.
75. Raji A, Seely EW, Bekins SA et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172-178.
76. Akazawa S, Sun F, Ito M et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23: 1067-1071.
77. Kelly DE, McKolanis TM, Kelley CA. Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in type 2 diabetes mellitus. Diabetes 2002; 51 (Suppl. 2): A35.
78. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distriubution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-2791.
79. Bakris G, Weston WM, Rappaport EB et al. Rosiglitazone produces long-term reduction in urinary albumin excretion in type 2 diabets. Diabetologia 1999; 42 (Suppl. 1): A230.
80. Yang L, An HX, Deng XL et al. Rosiglitazone reverses insulin secretion altered by chronic exposure to free fatty acid via IRS-2-associated phosphatidylinositol 3-kinase pathway. Acta Pharmacologica Sinica 2003; 24: 429-434.
81. Finegood DT, McArthur MD, Kojwang D et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029.
82. Lister CA, Moore GBT, Piercy V et al. Rosiglitazone, but not metformin or glibenclamide, improves glycaemic control and increases islet insulin contenct. Diabetologia 1999; 42 (Suppl. 1): A150.
83. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002; 22: 924-929.
84. Wang CHW, Eisel RD, Liu PP et al. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003; 107: 1350-1354.
85. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-2948.
86. Malmberg K, Ryden L, Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
87. Van Den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-1367.
88. Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ 1993; 306: 1313-1318.
89. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.